The FDA issues safety alerts for EpiPen and EpiPen Jr Auto-Injectors; we should be drinking more water to reduce the effects of increased sugar intake; experts suggest actively working to protect mental health while on lockdown.
A safety alert went out last evening from the FDA about EpiPen 0.3-mg and EpiPen Jr 0.15-mg Auto-Injectors following a letter that manufacturer Mylan sent to healthcare providers. In the letter, Mylan warned about possible device malfunction on the part of the safety release, spontaneous device activation, and device removal from the carrier tube. All parties concerned should continue to periodically review the EpiPen instructions and inspect their devices before use. Pharmacists should also inspect the pens prior to dispensing them. As always, the FDA encourages everyone to report adverse events to its MedWatch Safety Information and Adverse Event Reporting Program.
Working remotely and being on lockdown may mean a change to our regular workday eating habits, namely in the form of more sugar, according to Forbes. Researchers believe we should increase our water intake as a result, to help lessen the effects from excess buildup of uric acid, which accumulates in our blood from the breakdown of purines. The uric acid itself results from excess sugar intake. Higher sugar levels in our blood can also signal such metabolic disorders as diabetes and heart disease/inflammation.
The National Alliance on Mental Health has suggested that we must actively work to combat any mental distress brought on by the coronavirus disease 2019 (COVID-19) pandemic, according to the organization’s website. With top worries that include anxiety, loneliness, and stress centered on getting sick, losing money, and risking exposure to the virus, experts offer several coping strategies. These include being more conscious of where we get our news from, taking time for self-care, helping others, and having activities lined up to distract ourselves.
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More